Wells Fargo
RXRX icon

Wells Fargo’s Recursion Pharmaceuticals RXRX Stock Holding History

Wells Fargo’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Buy
510,879
+273,963
+116% +$912K ﹤0.01% 3663
2026
Q1 		$727K Sell
236,916
-924,074
-80% -$3.57M ﹤0.01% 3936
2025
Q4 		$4.75M Buy
1,160,990
+359,625
+45% +$1.78M ﹤0.01% 2728
2025
Q3 		$3.91M Buy
801,365
+584,332
+269% +$3.07M ﹤0.01% 2770
2025
Q2 		$1.1M Sell
217,033
-386,695
-64% -$1.9M ﹤0.01% 3639
2025
Q1 		$3.19M Buy
603,728
+145,407
+32% +$1.06M ﹤0.01% 2763
2024
Q4 		$3.1M Buy
458,321
+343,304
+298% +$2.31M ﹤0.01% 2842
2024
Q3 		$758K Buy
115,017
+37,802
+49% +$271K ﹤0.01% 3724
2024
Q2 		$579K Buy
77,215
+18,698
+32% +$163K ﹤0.01% 3819
2024
Q1 		$583K Buy
58,517
+6,547
+13% +$72.9K ﹤0.01% 3788
2023
Q4 		$512K Sell
51,970
-192,914
-79% -$1.38M ﹤0.01% 3849
2023
Q3 		$1.87M Buy
244,884
+131,612
+116% +$1.31M ﹤0.01% 2847
2023
Q2 		$846K Buy
113,272
+24,644
+28% +$172K ﹤0.01% 3581
2023
Q1 		$591K Buy
88,628
+86,603
+4,277% +$687K ﹤0.01% 3725
2022
Q4 		$15.6K Buy
2,025
+301
+17% +$2.95K ﹤0.01% 5366
2022
Q3 		$19K Buy
1,724
+338
+24% +$3.42K ﹤0.01% 5433
2022
Q2 		$12K Sell
1,386
-8,658
-86% -$57.9K ﹤0.01% 5677
2022
Q1 		$71K Sell
10,044
-40,601
-80% -$431K ﹤0.01% 5483
2021
Q4 		$868K Buy
50,645
+50,632
+389,477% +$953K ﹤0.01% 4230
2021
Q3 		$0 Buy
+13
New +$368 ﹤0.01% 7426

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's RXRX Position: Q2 2026 in Review

Wells Fargo increased its Recursion Pharmaceuticals (RXRX) stake by 116% in Q2 2026, buying an estimated $912K and bringing the position to 510,879 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3663.

Wells Fargo first reported a position in RXRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $4.75M in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Wells Fargo held 510,879 shares of Recursion Pharmaceuticals worth $1.87M as of Q2 2026.
  • Wells Fargo bought 273,963 Recursion Pharmaceuticals shares in Q2 2026, an estimated $912K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3663 holding.
  • Wells Fargo first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Wells Fargo's Recursion Pharmaceuticals position peaked at $4.75M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.